Tracey Walker, Contributing Editor
Studies: Lurasidone effective for treating depression associated with bipolar disorder
Lurasidone HCl (Latuda) reduces depressive symptoms in adult patients with bipolar depression when used as monotherapy and adjunctive therapy to lithium or valproate. This flexibility is important given the multiple unmet needs of patients with bipolar depression, according to two phase 3 studies published recently in The American Journal of Psychiatry.
Data from 4 HCV clinical trials presented at Liver Meeting in D.C.
Representatives of Boehringer Ingelheim reported the data at the 64th Annual Meeting of the American Association for the Study of Liver Diseases.
Investigational tiotropium reduces exacerbations in severe asthma cases
Once-daily dosing of the investigational drug tiotropium helped to improve lung function over 24 hours in individuals with severe asthma, according to data presented at the 2013 American College of Chest Physicians annual meeting (CHEST 2013) in Chicago.
Under breakthrough therapy designation, FDA approves chronic lymphocytic leukemia drug
FDA has approved obinutuzumab (Gazyva, Genentech, a member of the Roche Group), also known as GA101, in combination with chlorambucil chemotherapy for the treatment of patients with previously untreated chronic lymphocytic leukemia.
Allopurinol alone found inadequate for gout control
Allopurinol, considered the standard of care for gout, may be inadequate to lower uric acid levels in patients with gout, according to new safety and efficacy data from a large study presented at the American College of Rheumatology 2013 annual meeting recently in San Diego, Calif.
New once-daily COPD Rx available in U.S. pharmacies
New once-daily COPD Rx available in U.S. pharmacies
Fluticasone furoate and vilanterol inhalation powder (Breo Ellipta, GlaxoSmithKline and Theravance) once-daily for chronic obstructive pulmonary disease, is now available to pharmacies throughout the United States.
FDA approves extended-release, single-entity hydrocodone product
FDA has approved hydrocodone bitartrate extended-release capsules (Zohydro ER, Zogenix) for the management of pain severe enough to require daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate.
Study highlights need to address anaphylaxis prevention
Severe life-threatening allergic reactions are more common than many thought. Anaphylaxis very likely occurs in nearly 1 in 50 Americans (1.6%), and the rate is probably higher, close to 1 in 20 (5.1%), according to a study published in the Journal of Allergy and Clinical Immunology.
Opsumit approved to treat pulmonary arterial hypertension
FDA approved macitentan (Opsumit, Actelion Pharmaceuticals) to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or lung transplantation.
Antibiotics overprescribed for sore throats, bronchitis
Vast majorities of people who see physicians for sore throats or acute bronchitis receive antibiotics, yet only a small percentage should, according to analyses of 2 major national surveys presented recently at the IDWeek Meeting in San Francisco


View Results